<?xml version='1.0' encoding='utf-8'?>
<document id="31871092"><sentence text="Differential Impact of Nevirapine on Artemether-Lumefantrine Pharmacokinetics in Individuals Stratified by CYP2B6 c.516G&gt;T Genotypes."><entity charOffset="23-33" id="DDI-PubMed.31871092.s1.e0" text="Nevirapine" /></sentence><sentence text="There is an increased recognition of the need to identify and quantify the impact of genetic polymorphisms on drug-drug interactions" /><sentence text=" This study investigated the pharmacogenetics of the pharmacokinetic drug-drug interaction between nevirapine and artemether-lumefantrine in HIV-positive and HIV-negative adult Nigerian subjects"><entity charOffset="99-109" id="DDI-PubMed.31871092.s3.e0" text="nevirapine" /><entity charOffset="125-137" id="DDI-PubMed.31871092.s3.e1" text="lumefantrine" /><pair ddi="false" e1="DDI-PubMed.31871092.s3.e0" e2="DDI-PubMed.31871092.s3.e0" /><pair ddi="false" e1="DDI-PubMed.31871092.s3.e0" e2="DDI-PubMed.31871092.s3.e1" /></sentence><sentence text=" Thirty each of HIV-infected patients on nevirapine-based antiretroviral therapy and HIV-negative volunteers without clinical malaria, but with predetermined CYP2B6 c"><entity charOffset="41-51" id="DDI-PubMed.31871092.s4.e0" text="nevirapine" /></sentence><sentence text="516GG and TT genotypes, were administered a complete treatment dose of 3 days of artemether-lumefantrine"><entity charOffset="92-104" id="DDI-PubMed.31871092.s5.e0" text="lumefantrine" /></sentence><sentence text=" Rich pharmacokinetic sampling prior to and following the last dose was conducted, and the plasma concentrations of artemether/dihydroartemisinin and lumefantrine/desbutyl-lumefantrine were quantified using tandem mass spectrometry"><entity charOffset="116-126" id="DDI-PubMed.31871092.s6.e0" text="artemether" /><entity charOffset="127-145" id="DDI-PubMed.31871092.s6.e1" text="dihydroartemisinin" /><entity charOffset="150-162" id="DDI-PubMed.31871092.s6.e2" text="lumefantrine" /><entity charOffset="163-184" id="DDI-PubMed.31871092.s6.e3" text="desbutyl-lumefantrine" /><pair ddi="false" e1="DDI-PubMed.31871092.s6.e0" e2="DDI-PubMed.31871092.s6.e0" /><pair ddi="false" e1="DDI-PubMed.31871092.s6.e0" e2="DDI-PubMed.31871092.s6.e1" /><pair ddi="false" e1="DDI-PubMed.31871092.s6.e0" e2="DDI-PubMed.31871092.s6.e2" /><pair ddi="false" e1="DDI-PubMed.31871092.s6.e0" e2="DDI-PubMed.31871092.s6.e3" /><pair ddi="false" e1="DDI-PubMed.31871092.s6.e1" e2="DDI-PubMed.31871092.s6.e1" /><pair ddi="false" e1="DDI-PubMed.31871092.s6.e1" e2="DDI-PubMed.31871092.s6.e2" /><pair ddi="false" e1="DDI-PubMed.31871092.s6.e1" e2="DDI-PubMed.31871092.s6.e3" /><pair ddi="false" e1="DDI-PubMed.31871092.s6.e2" e2="DDI-PubMed.31871092.s6.e2" /><pair ddi="false" e1="DDI-PubMed.31871092.s6.e2" e2="DDI-PubMed.31871092.s6.e3" /></sentence><sentence text=" Pharmacokinetic parameters of artemether-lumefantrine and its metabolites in HIV-infected patients on nevirapine were compared to those in the absence of nevirapine in HIV-negative volunteers"><entity charOffset="42-54" id="DDI-PubMed.31871092.s7.e0" text="lumefantrine" /><entity charOffset="103-113" id="DDI-PubMed.31871092.s7.e1" text="nevirapine" /><entity charOffset="155-165" id="DDI-PubMed.31871092.s7.e2" text="nevirapine" /><pair ddi="false" e1="DDI-PubMed.31871092.s7.e0" e2="DDI-PubMed.31871092.s7.e0" /><pair ddi="false" e1="DDI-PubMed.31871092.s7.e0" e2="DDI-PubMed.31871092.s7.e1" /><pair ddi="false" e1="DDI-PubMed.31871092.s7.e0" e2="DDI-PubMed.31871092.s7.e2" /><pair ddi="false" e1="DDI-PubMed.31871092.s7.e1" e2="DDI-PubMed.31871092.s7.e1" /><pair ddi="false" e1="DDI-PubMed.31871092.s7.e1" e2="DDI-PubMed.31871092.s7.e2" /></sentence><sentence text=" Overall, nevirapine reduced exposure to artemether and desbutyl-lumefantrine by 39 and 34%, respectively"><entity charOffset="10-20" id="DDI-PubMed.31871092.s8.e0" text="nevirapine" /><entity charOffset="41-51" id="DDI-PubMed.31871092.s8.e1" text="artemether" /><entity charOffset="56-77" id="DDI-PubMed.31871092.s8.e2" text="desbutyl-lumefantrine" /><pair ddi="false" e1="DDI-PubMed.31871092.s8.e0" e2="DDI-PubMed.31871092.s8.e0" /><pair ddi="false" e1="DDI-PubMed.31871092.s8.e0" e2="DDI-PubMed.31871092.s8.e1" /><pair ddi="false" e1="DDI-PubMed.31871092.s8.e0" e2="DDI-PubMed.31871092.s8.e2" /><pair ddi="false" e1="DDI-PubMed.31871092.s8.e1" e2="DDI-PubMed.31871092.s8.e1" /><pair ddi="false" e1="DDI-PubMed.31871092.s8.e1" e2="DDI-PubMed.31871092.s8.e2" /></sentence><sentence text=" These reductions were significantly greater in GG versus TT subjects for artemether (ratio of geometric mean [90% confidence interval]: 0" /><sentence text="42 [0" /><sentence text="29 to 0" /><sentence text="61] versus 0" /><sentence text="81 [0" /><sentence text="51 to 1" /><sentence text="28]) and for desbutyl-lumefantrine (0"><entity charOffset="13-34" id="DDI-PubMed.31871092.s15.e0" text="desbutyl-lumefantrine" /></sentence><sentence text="56 [0" /><sentence text="43 to 0" /><sentence text="74] versus 0" /><sentence text="75 [0" /><sentence text="56 to 1" /><sentence text="00])" /><sentence text=" On the contrary, it increased exposure to dihydroartemisinin and lumefantrine by 47 and 30%, respectively"><entity charOffset="43-61" id="DDI-PubMed.31871092.s22.e0" text="dihydroartemisinin" /><entity charOffset="66-78" id="DDI-PubMed.31871092.s22.e1" text="lumefantrine" /><pair ddi="false" e1="DDI-PubMed.31871092.s22.e0" e2="DDI-PubMed.31871092.s22.e0" /><pair ddi="false" e1="DDI-PubMed.31871092.s22.e0" e2="DDI-PubMed.31871092.s22.e1" /></sentence><sentence text=" These increases were significantly higher in TT versus GG subjects for dihydroartemisinin (1"><entity charOffset="72-90" id="DDI-PubMed.31871092.s23.e0" text="dihydroartemisinin" /></sentence><sentence text="67 [1" /><sentence text="20 to 2" /><sentence text="34] versus 1" /><sentence text="25 [0" /><sentence text="88 to 1" /><sentence text="78]) and for lumefantrine (1"><entity charOffset="13-25" id="DDI-PubMed.31871092.s29.e0" text="lumefantrine" /></sentence><sentence text="51 [1" /><sentence text="20 to 1" /><sentence text="90] versus 1" /><sentence text="08 [0" /><sentence text="82 to 1" /><sentence text="42])" /><sentence text=" This study underscores the importance of incorporating pharmacogenetics into all drug-drug interaction studies with potential for genetic polymorphisms to influence drug disposition" /><sentence text="" /></document>